Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125365
Filing Date
2024-11-12
Accepted
2024-11-12 16:08:34
Documents
74
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ocx-20240930.htm   iXBRL 10-Q 2983838
2 EX-10.6 ocx-ex10_6.htm EX-10.6 21219
3 EX-31.1 ocx-ex31_1.htm EX-31.1 13073
4 EX-31.2 ocx-ex31_2.htm EX-31.2 12973
5 EX-32.1 ocx-ex32_1.htm EX-32.1 9205
  Complete submission text file 0000950170-24-125365.txt   13212908

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ocx-20240930.xsd EX-101.SCH 1650216
76 EXTRACTED XBRL INSTANCE DOCUMENT ocx-20240930_htm.xml XML 2692019
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37648 | Film No.: 241448110
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)